VERSES® Announces Consolidation of Class A Subordinate Voting Shares
VANCOUVER, British Columbia, June 20, 2025 (GLOBE NEWSWIRE) — VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSD) ('VERSES'' or the 'Company'), a cognitive computing company specializing in next-generation agentic software systems, announces the Company is consolidating all of its issued and outstanding Class A Subordinate Voting Shares (the 'Subordinate Voting Shares') on the basis of one (1) post-consolidated Subordinate Voting Share for every three (3) pre-consolidated Subordinate Voting Shares held (the 'Consolidation'). The Company's stock symbol will change to VRSSD following the Consolidation.
The Company's board of directors approved the Consolidation on June 10, 2025. Trading of the Subordinate Voting Shares on a post-Consolidation basis on Cboe Canada Inc. ('Cboe') is expected to commence on or about June 23, 2025. The new CUSIP number for the Subordinate Voting Shares will be 92539Q604 and the new ISIN number will be CA92539Q6040.
As of the date hereof, the Company currently has 26,239,469 Subordinate Voting Shares issued and outstanding. The Consolidation will reduce the number of outstanding Subordinate Voting Shares to approximately 8,746,490 Subordinate Voting Shares issued and outstanding.
Holders of physical share certificates of the Company are required to complete and return a letter of transmittal to the Company's transfer agent, Endeavor Trust Corporation, in order to receive their post-Consolidation Subordinate Voting Shares. Please visit
www.endeavortrust.com
for guidance on the process for returning your pre-consolidation share certificates and receiving your post-Consolidation Subordinate Voting Shares. Shareholders whose shares are represented by a direct registration system statement will automatically receive their post-Consolidation Subordinate Voting Shares without any further action. Shareholders who hold their shares through an intermediary are encouraged to contact their intermediaries if they have any questions.
No fractional Subordinate Voting Shares will be issued under the Consolidation as fractional Subordinate Voting Shares will be rounded either up or down to the nearest whole number of Subordinate Voting Shares. The exercise price and number of Subordinate Voting Shares issuable pursuant to the exercise of any outstanding convertible securities, including incentive stock options and warrants, will also be adjusted in accordance with the Consolidation ratio.
About VERSES
VERSES® is a cognitive computing company building next-generation intelligent software systems modeled after the wisdom and genius of Nature. Designed around first principles found in science, physics and biology, our flagship product, Genius,™ is an agentic enterprise intelligence platform designed to generate reliable domain-specific predictions and decisions under uncertainty. Imagine a Smarter World that elevates human potential through technology inspired by Nature. Learn more at
verses.ai
,
LinkedIn
and
X
.
On behalf of the Company
Gabriel René, Founder & CEO, VERSES AI Inc.
Press Inquiries:
press@verses.ai
Investor Relations Inquiries
James Christodoulou, Chief Financial Officer
IR@verses.ai
, +1(212)970-8889
Cautionary Note Regarding Forward-Looking Statements
This news release contains statements which constitute 'forward-looking information' or 'forward-looking statements' within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and plans of the Company. Forward-looking information and forward-looking statements are often identified by the words 'may', 'would', 'could', 'should', 'will', 'intend', 'plan', 'anticipate', 'believe', 'estimate', 'expect' or similar expressions. More particularly and without limitation, this news release contains forward–looking statements and information relating to the expectation that the Company will complete the Consolidation; the effective date of the Consolidation; the number of Subordinate Voting Shares outstanding following the Consolidation; the treatment of fractional shares in the Consolidation; and other statements that are not historical facts.
The forward–looking statements and information are based on certain key expectations and assumptions made by the management of the Company. As a result, there can be no assurance that such plans will be completed as proposed or at all. Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that the Company will complete the Consolidation; that the Company will receive the necessary approvals to complete the Consolidation; that the number of Subordinate Voting Shares outstanding following the Consolidation will be consistent with the number set out herein; and that the treatment of fractional shares will align with management's current expectations. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward–looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward–looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to complete the Consolidation on the effective date, or at all; the number of post-Consolidation Subordinate Voting Shares may be different from the number set out herein and other risks detailed from time to time in the filings made by the Company in accordance with securities regulations. Accordingly, readers should not place undue reliance on the forward–looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.
The forward–looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward–looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) ('Lipella' or the 'Company'), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Specifically, Nasdaq cited the issuance of Series C voting convertible preferred stock and warrants to the Company's placement agent and advisor to those transactions, as having been structured in a way that triggered these rule violations. The Company was notified by the Hearings Panel of its determination to delist the Company's common stock effective today. Lipella is disappointed by this decision—particularly in light of the fact that it was taking immediate steps to obtain stockholder approval and address the concerns raised by Nasdaq. Lipella remains operationally sound, and its business fundamentals are intact. The Company is executing on its strategic and clinical development plans, including continued advancement of its lead product candidates LP-10 for hemorrhagic cystitis and LP-310 for oral lichen planus. In parallel, Lipella is actively exploring other markets to list its common stock and is committed to relisting its shares on a trading venue that provides the best possible liquidity and access for investors. The Company's common stock is currently quoted on the OTC Markets under the symbol 'LIPO.' 'We acknowledge Nasdaq's decision and are focused on taking swift, constructive steps accordingly,' said Dr. Jonathan Kaufman, Chief Executive Officer of Lipella. 'Our commitment to our shareholders, our mission, and our clinical goals has not changed.' The Company remains a reporting company under the Securities Exchange Act of 1934 and will continue to file periodic reports and disclosures with the U.S. Securities and Exchange Commission. Lipella will keep its stockholders informed of all material developments as it continues to assess its options. About Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals is a clinical-stage biotechnology company focused on developing new drugs by reformulating active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella targets diseases with significant unmet needs, where no approved drug therapies currently exist. The company completed its initial public offering in 2022. Learn more at and follow us on X and LinkedIn. Forward-Looking Statements This press release includes certain "forward-looking statements." All statements, other than statements of historical fact, included in this press release regarding, among other things, our strategy, including with respect to the Company's exploration of all markets and its commitment to list its common stock, future operations, financial position, prospects, clinical trials, regulatory approvals, pipeline and opportunities, sources of growth, successful implementation of our proprietary technology, plans and objectives are forward-looking statements. Forward-looking statements can be identified by words such as "may," "will," "could," "continue," "would," "should," "potential," "target," "goal," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "predicts," "expects," "projects" and similar references to future periods. Forward-looking statements are based on our current expectations and assumptions regarding future events and financial trends that we believe may affect among other things, market and other conditions, our financial condition, results of operations, business strategy, short- and long-term business operations and objectives, and financial needs. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you, therefore, against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. There are risks, uncertainties and other factors, both known and unknown, that could cause actual results to differ materially from those in the forward-looking statements which include, but are not limited to, general capital market risks, regional, national or global political, economic, business, competitive, market and regulatory conditions, and other risks that may be included in the periodic reports and other filings that the Company files from time to time with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us is based upon the reasonable judgment of our management at the time such statement is made and speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Nothing contained herein is, or shall be relied upon as, a promise or representation as to the past or future. In addition, the information contained in this press release is as of the date hereof, and the Company has no obligation to update such information, including in the event that such information becomes inaccurate. You should not construe the contents of this press release as legal, tax and financial advisors as to legal and related matters concerning the matters described herein. CONTACT:Jonathan KaufmanChief Executive OfficerLipella Pharmaceuticals PCG AdvisoryJeff Ramsonjramson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
How Boston Red Sox trading Rafael Devers affects 2025 CBT payroll, beyond
SEATTLE — The Red Sox got the San Francisco Giants to take on all $271.153 million of the remaining money on Rafael Devers' contract as part of Sunday's blockbuster trade. Boston also acquired pitchers Jordan Hicks and Kyle Harrison and prospects James Tibbs III and Jose Bello. Advertisement The Red Sox will play here in Seattle against the Mariners at T-Mobile Park on Monday, which will be the first day of the post-Devers Era. Devers signed a 10-year, $313.5 million contract extension in January 2023 that went into effect at the beginning of the 2024 season. Boston ended up paying only $42.347 million of it, including $12.847 million this year. The Giants will pay him $16.653 million this season, then $254.5 million over the next eight seasons. Devers' average annual value counting toward the competitive balance tax threshold is $29 million per season. So the Red Sox' CBT hit for Devers this year will be approximately $12.629 million. The Giants' CBT hit will be $16.371 million. Advertisement The Red Sox' 2025 projected payroll is now 'relatively close' to the $241 million CBT base threshold, according to a source. The Red Sox will take on the $32.056 million remaining on Hicks' contract, a four-year, $44 million deal signed before last season. He will count approximately $6.2 million toward Boston's 2025 CBT payroll and $11 million each of the next two seasons. The Red Sox have won eight of their past 10 games. The plan as of now is to add at the trade deadline, according to a source familiar with the team's thinking. And so the payroll is expected to be above $241 million at the end of the season. Eliminating Devers' $29 million average annual value will give them plenty of payroll flexibility in 2026 and beyond. His deal expires in 2033. More Red Sox coverage Read the original article on MassLive.
Yahoo
an hour ago
- Yahoo
Is Cboe Global Stock Outperforming the Nasdaq?
Cboe Global Markets, Inc. (CBOE) is a leading global exchange operator and financial technology firm, headquartered in Chicago and employing around 1,650 people. With a market cap of $23.6 billion, it spans trading venues across North America, Europe, and Asia-Pacific. Companies with a market value of $10 billion or more are classified as 'large-cap stocks,' Cboe Global holds its place in this category. It leads the U.S. options market and is the originator of the VIX volatility index, giving it a unique edge in volatility-driven trading. Its consistent innovation, regulatory expertise, and scale position it as a key player in capital markets infrastructure, capable of capitalizing on both market volatility and long-term trading trends. Is Palantir Stock Poised to Surge Amidst the Israel-Iran Conflict? 'It Has No Utility': Warren Buffett Doesn't Care How High Gold Goes, He Isn't a Buyer OpenAI CEO Sam Altman Says 'We Are Heading Towards a World Where AI Will Just Have Unbelievable Context on Your Life' Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Cboe Global shares are currently trading 3.6% below its 52-week high of $236.02, which they touched recently on May 8. The stock has climbed 3.6% over the past three months, underperforming the broader Nasdaq Composite's ($NASX) 11.7% rise over the same time frame. However, on a year-to-date basis, CBOE has delivered a standout performance, surging 16.5% and handily outperforming the Nasdaq's modest 1.2% return. The outperformance extends over the longer horizon as well, with CBOE boasting a 34.4% gain over the past 52 weeks, far exceeding the Nasdaq's 9.4% rise during the same period. Since July last year, CBOE has remained above its 200-day moving average and has mostly traded over its 50-day moving average since early April. On May 2, shares of Cboe Global Markets rose over 2% following the release of its Q1 results, which exceeded expectations on both earnings and revenue. The company reported adjusted EPS of $2.50, surpassing consensus estimates by 5.9%, while adjusted revenue came in at $565.2 million, topping forecasts by 1.5%. It upgraded full-year guidance, with revenue growth now projected in the mid-to-high single-digit range, thanks to continued investment in tech platforms, global expansion, and Data Vantage. CBOE's rival, CME Group Inc. (CME), has outperformed the stock and gained 38.5% over the past 52 weeks and 17.2% in 2025. Analysts maintain a cautious outlook on its prospects. CBOE has a consensus rating of 'Hold' from the 17 analysts covering the stock and is currently trading above its mean price target of $225. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
